INFLUENCE OF THE ADMINISTRATION SCHEDULE ON THE THERAPEUTIC EFFECT OF INTERLEUKIN-2

被引：23

作者：

VAAGE, J ^{[1
]}

PAULY, JL ^{[1
]}

HARLOS, JP ^{[1
]}

机构：

[1] NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT MOLEC IMMUNOL,BUFFALO,NY 14263

来源：

关键词：

D O I：

10.1002/ijc.2910390421

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：530 / 533

页数：4

共 27 条

[1] GROWTH-INHIBITION OF AN MC-INDUCED MOUSE SARCOMA BY TCGF (IL 2)-CONTAINING PREPARATIONS - PRELIMINARY-REPORT
BUBENIK, J
PERLMANN, P
INDROVA, M
SIMOVA, J
JANDLOVA, T
NEUWIRT, J
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1983, 14 (03) : 205 - 206
[2] BUBENIK J, 1986, FOLIA BIOL-PRAGUE, V32, P209
[3] BUBENIK J, 1985, CANCER IMMUNOL IMMUN, V19, P57
[4] AUGMENTATION OF THE ANTI-TUMOR THERAPEUTIC EFFICACY OF LONG-TERM CULTURED LYMPHOCYTES-T BY INVIVO ADMINISTRATION OF PURIFIED INTERLEUKIN-2
CHEEVER, MA
GREENBERG, PD
FEFER, A
GILLIS, S
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (04) : 968 - 980
[5] CHEEVER MA, 1984, J IMMUNOL, V132, P2259
[6] CLONED CELL-LINES WITH NATURAL-KILLER ACTIVITY - SPECIFICITY, FUNCTION, AND CELL-SURFACE MARKERS
DENNERT, G
YOGEESWARAN, G
YAMAGATA, S
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 153 (03) : 545 - 556
[7] DONOHUE JH, 1984, J IMMUNOL, V132, P2123
[8] DONOHUE JH, 1983, J IMMUNOL, V130, P2203
[9] EBERLEIN TJ, 1982, J EXP MED, V156, P385
[10] FORNI G, 1985, J IMMUNOL, V134, P1305